✦ LIBER ✦

Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials

✍ Scribed by Norman K. Hollenberg

Book ID: 117600993
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 45 KB
Volume: 15
Category: Article
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(02)02424-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of Information on Reported Advers

Effect of Information on Reported Adverse Events in a Placebo-Controlled Trial

✍ Dr Michael Ossege, Thomas Sycha, Martin Aigner, Leopold Schmetterer, Hans-Georg 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 118 KB

LB17 Safety of tolterodine PR in childre

LB17 Safety of tolterodine PR in children with detrusor overactivity: Pooled data from two large placebo-controlled trials

✍ R. Nijman; N. Borgstein; P. Ellsworth 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Safety of Hypericum extract in mildly to

Safety of Hypericum extract in mildly to moderately depressed outpatients: A review based on data from three randomized, placebo-controlled trials

✍ R.D. Trautmann-Sponsel; Angelika Dienel 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 285 KB

127. The Effect of Adverse Events on Cli

127. The Effect of Adverse Events on Clinical Outcome Analysis of Data from an FDA IDE Trial

✍ William Bodemer; Donna Ohnmeiss; Jack Zigler 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Safety and tolerability of duloxetine in

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random

Statin and the Risk of Renal-Related Ser

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

✍ Bangalore, Sripal; Fayyad, Rana; Hovingh, G. Kees; Laskey, Rachel; Vogt, Liffert 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 216 KB